Background: Wixela (TM) Inhub (TM) is a fluticasone propionate/salmeterol dry powder inhaler developed as a generic equivalent of Advair Diskus(R) for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Wixela Inhub and Advair Diskus are comparable in terms of functionality...
generic drugsBackground: Wixela (R) Inhub (R) is a dry powder inhaler approved as a generic equivalent to Advair (R) Diskus (R) (fluticasone propionate [FP]/salmeterol fixed-dose combination) for patients with asthma or chronic obstructive pulmonary disease (COPD). This study aimed at ...
Fluticasone propionate/salmeterol (Wixela Inhub) dry-powder inhaler in asthma and COPD: a profile of its use in the USAWixela Inhub is the first therapeutically equivalent, substitutable generic version of Advair Diskus (fluticasone propionate/salmeterol) approved for the treatment of asthma and ...
Background:Wixela Inhub is a generic version of Advair Diskus recently approved by the U.S. Food and Drug Administration. The Inhub inhaler delivers fluticasone propionate (FP)/salmeterol in a dry powder formulation. The goals of our studies were to demonstrate that the Inhub inhaler can be ...